Founded in 2011 and headquartered in Spain with facilities in Belgium, Minoryx is a clinical-stage biotech company that specializes in the development of novel treatments for orphan central nervous system diseases with high unmet medical needs. Their lead program, leriglitazone (MIN-102), is a brain penetrant and selective PPARγ agonist being evaluated for X-linked Adrenoleukodystrophy (X-ALD) and Friedreich’s Ataxia. With the support of experienced investors and a network of organizations, Minoryx has raised over €120 million and is committed to finding innovative treatments for life-threatening rare diseases, particularly in the pediatric population. They focus on developing pharmacological chaperones, a new generation of small molecule drugs, as well as repositioning-based projects to address genetic diseases severely affecting the central nervous system.